May 6, 2020 / 11:39 AM / a month ago

BRIEF-Mesoblast Says First Patients Dosed In Controlled Trial Of Remestemcel-L For Covid-19 Acute Respiratory Distress Syndrome

May 6 (Reuters) - Mesoblast Ltd:

* FIRST PATIENTS DOSED IN PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF MESOBLAST’S REMESTEMCEL-L FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below